Titer Analysis In The Era Of Complex Antibody Therapeutics

By Kelly Flook, PhD, Senior Manager – Product Management, Thermo Fisher Scientific

As antibody-based therapeutics evolve beyond conventional monoclonal antibodies into more complex modalities such as bispecifics, antibody–drug conjugates, and Fc-engineered variants, the analytical approaches used to characterize these molecules must evolve accordingly. Among the most critical analytical attributes is titer, which provides essential insight into process performance, manufacturing yield, and commercial viability. However, as molecular complexity increases and upstream and downstream processes introduce greater heterogeneity, accurately measuring titer becomes far more challenging than obtaining a simple concentration value.

Many commonly used quantification techniques assume a relatively pure sample and minimal analytical interference. While this assumption may be valid in late-stage development, final formulation, or QC release testing, where materials are highly purified and excipients are well characterized, it breaks down in earlier process stages. Crude and partially purified samples contain a complex mixture of host cell proteins, nucleic acids, media components, and buffer additives that can obscure true product concentration and compromise measurement accuracy.

Chromatography addresses these challenges by combining separation with quantification. Rather than relying solely on bulk signal intensity, chromatographic methods isolate the target molecule from the surrounding matrix, enabling accurate and selective titer measurement even when the analyte represents a small fraction of the sample. This separation-enabled approach provides flexibility across the development lifecycle, supporting high-resolution analysis in early development and streamlined, robust workflows for routine manufacturing and quality control.